Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

UK JCVI Not Recommends Novartis's Meningitis B Vaccine Bexsero For Immunization

RELATED NEWS
Trade NVS now with 

Swiss drug maker Novartis AG (NVS: Quote), Wednesday said the UK Joint Committee on Vaccination and Immunisation or JCVI took an interim position to not recommend Bexsero vaccine for inclusion in the National Immunisation Programme, driven by evaluation based on cost-effectiveness assumptions. The company added that the JCVI does not feel that the decision is in the interest of the public.

Novartis said the JCVI made its evaluation before any pricing discussion with it and if the position is not changed, it will postpone Bexsero access.

In January 2013, the European Medicines Agency licensed Bexsero for active immunization of individuals from two months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.